1. Home
  2. DLPN vs LNAI Comparison

DLPN vs LNAI Comparison

Compare DLPN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • LNAI
  • Stock Information
  • Founded
  • DLPN 1996
  • LNAI N/A
  • Country
  • DLPN United States
  • LNAI United States
  • Employees
  • DLPN N/A
  • LNAI N/A
  • Industry
  • DLPN Other Consumer Services
  • LNAI Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • LNAI Health Care
  • Exchange
  • DLPN Nasdaq
  • LNAI Nasdaq
  • Market Cap
  • DLPN 21.8M
  • LNAI 22.3M
  • IPO Year
  • DLPN N/A
  • LNAI N/A
  • Fundamental
  • Price
  • DLPN $1.59
  • LNAI $0.85
  • Analyst Decision
  • DLPN Strong Buy
  • LNAI
  • Analyst Count
  • DLPN 1
  • LNAI 0
  • Target Price
  • DLPN $5.00
  • LNAI N/A
  • AVG Volume (30 Days)
  • DLPN 42.7K
  • LNAI 8.8M
  • Earning Date
  • DLPN 11-12-2025
  • LNAI 10-03-2025
  • Dividend Yield
  • DLPN N/A
  • LNAI N/A
  • EPS Growth
  • DLPN N/A
  • LNAI N/A
  • EPS
  • DLPN N/A
  • LNAI N/A
  • Revenue
  • DLPN $51,257,243.00
  • LNAI N/A
  • Revenue This Year
  • DLPN $9.05
  • LNAI N/A
  • Revenue Next Year
  • DLPN $15.42
  • LNAI N/A
  • P/E Ratio
  • DLPN N/A
  • LNAI N/A
  • Revenue Growth
  • DLPN 4.84
  • LNAI N/A
  • 52 Week Low
  • DLPN $0.75
  • LNAI $0.81
  • 52 Week High
  • DLPN $1.88
  • LNAI $21.00
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 49.69
  • LNAI N/A
  • Support Level
  • DLPN $1.43
  • LNAI N/A
  • Resistance Level
  • DLPN $1.79
  • LNAI N/A
  • Average True Range (ATR)
  • DLPN 0.14
  • LNAI 0.00
  • MACD
  • DLPN -0.03
  • LNAI 0.00
  • Stochastic Oscillator
  • DLPN 29.78
  • LNAI 0.00

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About LNAI Lunai Bioworks Inc. Common Stock

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: